Navigation Links
Mr. Jean-Pierre Garnier Concludes his Mission at the Pierre Fabre Company
Date:6/28/2010

CASTRES, France, June 28, 2010 /PRNewswire/ -- Mr Jean-Pierre Garnier will step down on September 1st 2010, two years after having been appointed CEO of the Pierre Fabre Group.

"The Company is in excellent health, and is poised to experience a bright future ; I am glad to have contributed to its success and I take this opportunity to thank Mr. Pierre Fabre, visionary founder, for having entrusted me with this important mission".

Mr. Pierre Fabre thanked Mr Jean-Pierre Garnier for his "commitment and the excellent work performed" and stated that "his contribution over the past two years has been of the utmost benefit to the Company".

The new governance, which will continue in the spirit of the current organisation, will be announced in the near future.

    About Pierre Fabre group :

    The Pierre Fabre Group, the second largest independent French
    pharmaceutical company and leader in the field of in-pharmacy
    dermocosmetics, employs about 10,000 people worldwide, including 1,400 R&D
    staff, and generates a turnover of EUR 1.8 billion.

    In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to
    R&D in four priority therapeutic areas in public health: oncology, central
    nervous system, dermatology, cardio-vascular/metabolism.

    To learn more about Pierre Fabre, please refer to
    http://www.pierre-fabre.com.

    Press Contact :

    Djamila Hazene-Kedjem
    djamila.hazene.kedjem@pierre-fabre.com
    +33(0)1-49-10-81-72 / +33(6)89-45-87-95



'/>"/>
SOURCE Groupe Pierre Fabre
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
2. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
5. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
6. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
7. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
8. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
9. Indevus Announces Submission of New Drug Application
10. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
11. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):